Navigation Links
Bronchitol Cystic Fibrosis Dose Trial Results Positive
Date:8/11/2008

Bronchitol Demonstrates Dose-Related Improvements in Lung Function of

Cystic Fibrosis Patients

SYDNEY, Australia, Aug. 11 /Xinhua-PRNewswire-FirstCall/ -- Speciality pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced results from its Phase II trial, DPM-CF-202, in subjects with cystic fibrosis.

The trial achieved its primary end point of demonstrating a dose dependent improvement in lung function as measured by FVC (forced vital capacity) and FEV1 (the amount of air that can be forcibly exhaled in 1 second). At the end of the two-week Bronchitol treatment periods, changes in lung function were as follows:

-- 400 mg treatment group: FEV1 increased by 8.6%

(139 mls, p=0.0006 vs 40 mg)

-- 240 mg treatment group: FEV1 increased by 4.6% (87 mls)

-- 120 mg treatment group: FEV1 increased by 3.7% (42 mls)

-- 40 mg treatment group: FEV1 decreased by -1.6% (-33 mls)

FVC changed by +7.9% on 400 mg (p=0.0004 vs 40 mg), +3.9% on 240 mg, +1.5% on 120 mg and -0.6% on 40 mg.

Pharmaxis Chief Executive Officer Alan Robertson said, "The excellent result from this trial reaffirms that the 400 mg Bronchitol dose being used in the Phase 3 trials is optimal for its clinical effectiveness. We look forward to the results from the ongoing Phase 3 studies and to bringing Bronchitol to the market as rapidly as possible."

The study was an open, randomised comparison of 400mg, 240 mg, 120 mg and 40 mg of Bronchitol in 48 patients with cystic fibrosis at 12 centres across Canada and Argentina. Bronchitol was administered twice a day for 14 days in a crossover design.

Secondary endpoints of the study included other spirometry and quality of life measures. These measures also showed a positive effect for 400 mg Bronchitol on MMEF (maximum mid expiratory flow) and the respiratory domain of the cystic fibrosis quality of life questionnaire (CFQR).

Add
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmaxis Long-Term Safety Study of Bronchitol Completes
2. Pharmaxis Establishes Named Patient Program for Bronchitol
3. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
4. Promising Cystic Fibrosis Compound on Track for Development
5. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
6. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
7. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
8. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
9. Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting
10. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
11. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 UBM Medica ... a leading online community to help oncologists and other ... available regarding the use of targeted therapies and immunotherapies, ... research and treatment.  Every September, ... way to raise awareness about blood cancers—helping to increase ...
(Date:9/19/2014)... DALLAS , September 19, 2014 ... Market by Equipment Type (Benchtop, Mobile, Industrial, & ... Others), Technology (Tray-style, Manifold, & Rotary) & Geography ... by MarketsandMarkets, defines and segments the lyophilization market ... regions with analyses and projections of the market ...
(Date:9/19/2014)...  Lpath, Inc. (NASDAQ: LPTN ), ... today that it has entered into definitive agreements ... and 3,605,042 unregistered warrants in a registered direct ... share of common stock and one unregistered warrant ... will be $3.475.  The warrants have an exercise ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
... , , FARMINGDALE, N.Y., Jan. 11 Misonix, ... invasive ultrasonic medical device technology, which in Europe is ... other acute health conditions, has entered into a new, ... in Lima, Peru, for the distribution of the SonaStar(TM) ...
... , BETHESDA, Md., Jan. 11 Spherix Inc. (Nasdaq: ... a provider of technical and regulatory consulting services to food, ... Dr. Robert Lodder, will be presenting at the Annual OneMedPlace ... Drake Hotel in San Francisco, CA. Dr. Lodder will ...
Cached Medicine Technology:Misonix Announces New Distribution Agreement for Peru 2Misonix Announces New Distribution Agreement for Peru 3Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco 2Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco 3
(Date:9/20/2014)... The festival season is coming soon. The high-end fashion designer ... cocktail dresses . A lot of sophisticated women like its ... new promotion for its high quality clothes. Now, each of ... 20 to 71 percent off. , The company’s cocktail ... provided in many fashionable colors. Mary, the company’s sales manager, ...
(Date:9/20/2014)... September 20, 2014 Recently, Best ... site, has launched its new website. The new ... of popular hosting products for customers. Here, people ... make a purchasing decision. Also, it has recommended ... , One of the great web hosting ...
(Date:9/20/2014)... September 20, 2014 Plumbing construction ... out of 5, indicating a moderately favorable purchasing environment ... score reflects current and future pricing trends that will ... prices. Other factors that negatively affect buyer power are ... construction and the moderate switching costs. Buyers benefit, however, ...
(Date:9/20/2014)... 20, 2014 The Arizona Advanced ... is celebrating National Manufacturing Day by opening its doors ... processing and additive manufacturing labs will be offered between ... at MCC’s Southern and Dobson campus (1833 W. Southern ... Lot D. , The AzAMI at MCC was established ...
(Date:9/19/2014)... (PRWEB) September 20, 2014 Nearly 780 ... of Common Pleas where a meeting took place to ... complaints pending in the court’s mass tort program. ... meet this past week at the Complex Litigation Center ... consolidated for pretrial proceedings. The Risperdal lawsuits filed against ...
Breaking Medicine News(10 mins):Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4
... the future may be painless and noninvasive, thanks to smart ... test for skin cancer, patients today must endure doctors cutting ... lab and anxiously awaiting the results. Using laser microscopes that ... have the tools to painlessly scan a patient,s troublesome mole ...
... have discovered a signaling pathway that is crucial to ... data, obtained from cells, animals and ALI patients, suggest ... the targets significantly reduced flooding of the lungs that ... is a devastating disease, with 40 percent mortality and ...
... Researchers at Memorial Sloan-Kettering Cancer Center,s Nanotechnology ... Hybrid Silica Technologies, have received approval for their ... US Food and Drug Administration (FDA) for an ... imaging of cancer, which may be useful for ...
... a patient,s immune system and enables them to fight the ... first time in the UK. The treatment will use ... of Southampton, which will treat a selected group of volunteers ... forms of bone marrow and blood cancer. Scientists ...
... MONDAY, Jan. 31 (HealthDay News) -- A man is much more ... another woman than a girlfriend who had sex with another man, ... to stick with a man who had sex with another woman ... The findings provide new insight into the general male desire to ...
... Sprint Fidelis implantable cardioverter-defibrillator (ICD) leads (Medtronic) failed more ... heart disease, according to a multicenter study published online ... that lead failure was not associated with death or ... the patients whose leads fractured experienced painful inappropriate shocks, ...
Cached Medicine News:Health News:Smart lasers could make cancer biopsies painless, help speed new drugs to market 2Health News:Researchers discover signaling pathway crucial to acute lung injury 2Health News:Cancer-targeting investigational nanoparticle receives FDA IND approval for first-in-human trial 2Health News:Cancer-targeting investigational nanoparticle receives FDA IND approval for first-in-human trial 3Health News:Southampton scientists begin patient trials of new leukemia cancer vaccine 2Health News:Southampton scientists begin patient trials of new leukemia cancer vaccine 3Health News:Recalled ICD leads fail in women, youths most often 2
... with obstructive sleep apnea necessitating tracheotomy, or ... Also indicated where airway access for pulmonary ... ,Another excellent choice for a sleep apnea ... series. Available with a low profile inner ...
... additional patient safety, the laryngectomy ... integral 15 mm ISO termination ... a ventilator, with or without ... , ,Portex® laryngectomy tubes ...
... nature of the silicone tube material allows ... and more comfort than tubes made of ... comfortable and compliant neck flange allows the ... irritation. A comprehensive range of sizes insures ...
... that in excess of 10% of all ... a specialized tracheostomy tube. Bivona® Fixed-Flange Hyperflex™ ... and can adapt to the unique anatomical ... extra horizontal length, extra vertical length, ...
Medicine Products: